Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368797 | 0.83 | SLC6A9 (0.64) | P2RX7SLC6A9 | |
| SCHEMBL27684011 | 0.82 | SLC6A9 (0.53) | CHRM1P2RX7SLC6A9 | |
| SCHEMBL679425 | 0.82 | SLC6A9 (0.65) | SLC6A9 | |
| SCHEMBL8241368 | 0.80 | SLC6A9 (0.52) | P2RX7SLC6A9 | |
| SCHEMBL678925 | 0.79 | SLC6A9 (0.67) | SLC6A9 | |
| SCHEMBL8243684 | 0.79 | SLC6A9 (0.54) | P2RX7SLC6A9 | |
| SCHEMBL2903008 | 0.76 | SLC6A9 (0.70) | SLC6A9 | |
| SCHEMBL13208533 | 0.75 | SLC6A9 (0.67) | SLC6A9 | |
| SCHEMBL4371728 | 0.74 | SLC6A9 (0.70) | P2RX7SLC6A9 | |
| SCHEMBL12627234 | 0.74 | SLC6A9 (0.46) | P2RX7SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| EP-1942893-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007053400-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053400-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | CHRM1 1893/4885CHRM3 2284/4885P2RX7 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.